Navigation Links
Novelos Therapeutics To Present At The Benchmark 2012 Micro Cap Discovery Investor Conference On November 29
Date:11/27/2012

MADISON, Wis., Nov. 27, 2012 /PRNewswire/ -- Novelos Therapeutics, Inc. (OTCQX: NVLT), a pharmaceutical company developing novel drugs for the treatment and diagnosis of cancer, today announced that Harry Palmin, President and CEO of Novelos, will present a corporate update at the Benchmark 2012 Micro Cap Discovery Investor Conference on Thursday, November 29, 2012.  Mr. Palmin is scheduled to present at 10:00 a.m. CT.  The conference will take place at the InterContinental Hotel in Milwaukee and is being sponsored by Benchmark Company, LLC.

A live webcast of the Novelos presentation may be accessed via www.novelos.com
The webcast will be archived for 90 days following the presentation.

About Novelos Therapeutics, Inc.
We are a pharmaceutical company developing novel drugs for the treatment and diagnosis of cancer.  Our cancer-targeted compounds are selectively taken up and retained in cancer cells, including cancer stem cells, versus normal cells.  Thus, our therapeutic compounds appear to directly kill cancer cells while minimizing harm to normal cells.  This offers the potential for a paradigm shift in cancer therapy by providing efficacy versus all three major drivers of mortality in cancer: primary tumors, metastases and stem cell-based relapse.  I-124-CLR1404 (LIGHT) is a small-molecule, broad-spectrum, cancer-targeted PET imaging agent.  We believe LIGHT has first-in-class potential and Phase 1-2 clinical trials are ongoing across 11 solid tumor indications.  I-131-CLR1404 (HOT) is a small-molecule, broad-spectrum, cancer-targeted molecular radiotherapeutic that delivers cytotoxic radiation directly and selectively to cancer cells and cancer stem cells.  We believe HOT also has first-in-class potential.  HOT Phase 1b dose-escalation trial is ongoing and, subject to additional funding, we expect HOT to enter Phase 2 trials in the third quarter of 2013 as a monotherapy for solid tumors with significant unmet medical need.  CLR1502 (GLOW2) is a preclinical, cancer-targeted, non-radioactive optical imaging agent for intraoperative tumor margin illumination and non-invasive tumor imaging.  Together, we believe our compounds are able to "find, treat and follow" cancer anywhere in the body in a novel, effective and highly selective way.  For additional information please visit www.novelos.com

INVESTOR CONTACTS
J. Patrick Genn, Vice President of IR, Novelos Therapeutics, Inc., Madison, Wisc. & Boston, Mass., Ph: (858) 775-7456, Email: jpgenn@novelos.com

Anne Marie Fields, Senior Vice President, LHA, Ph: (212) 838-3777, Email: afields@lhai.com, @LHA_IR_PR

This news release contains forward-looking statements.  You can identify these statements by our use of words such as "may," "expect," "believe," "anticipate," "intend," "could," "estimate," "continue," "plans," or their negatives or cognates.  Such statements are valid only as of today, and we disclaim any obligation to update this information.  These statements are only estimates and predictions and are subject to known and unknown risks and uncertainties that may cause actual future experience and results to differ materially from the statements made.  These statements are based on our current beliefs and expectations as to such future outcomes.  Drug discovery and development involve a high degree of risk.  Factors that might cause such a material difference include, among others, uncertainties related to the ability to attract and retain partners for our technologies, the identification of lead compounds, the successful preclinical development thereof, the completion of clinical trials, the FDA review process and other government regulation, our  pharmaceutical collaborators' ability to successfully develop and commercialize drug candidates, competition from other pharmaceutical companies, product pricing and third-party reimbursement.

 


'/>"/>
SOURCE Novelos Therapeutics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Novelos Therapeutics Announces Successful Completion of First Cohort In Lung Cancer Trial With I-124-CLR1404 (LIGHT) Cancer-Targeted PET Imaging Agent at UW Carbone Cancer Center
2. Novelos Therapeutics Successfully Completes First Cohort In Phase 1b Solid Tumor Trial With I-131-CLR1404 (HOT) Cancer-Targeted Molecular Radiotherapeutic
3. Novelos Therapeutics Prices $5.4 Million Public Offering
4. Novelos Therapeutics to Present at LHA Life Sciences & Medical Technologies Virtual Conference on June 28
5. Novelos Therapeutics to Present at Rodman & Renshaw 14th Annual Healthcare Conference on September 11
6. Novelos Therapeutics And Academic Collaborators Present Three Posters At 2012 World Molecular Imaging Congress
7. Novelos Therapeutics Successfully Completes Second Cohort In Phase 1b Solid Tumor Trial With I-131-CLR1404 (HOT) Cancer-Targeted Molecular Radiotherapeutic
8. Novelos Therapeutics Announces Enrollment of First Patient in Solid Tumor Imaging Trial with I-124-CLR1404 (LIGHT) Cancer-targeted PET Imaging Agent at UW Carbone Cancer Center
9. Novelos Therapeutics Closes $2 Million Private Placement
10. Cell Therapeutics, Inc. (CTI) to Report First Quarter Financial Results on April 20
11. Faruqi & Faruqi, LLP Encourages Investors Who Suffered Substantial Losses Investing in Chelsea Therapeutics International, Ltd. to Contact the Firm
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/28/2017)... -- The global  pulse oximeters market  is expected to reach USD ... Inc. The pulse oximeters market is anticipated to witness significant growth during the ... such as chronic obstructive pulmonary disease (COPD), sleep apnea, cardiac arrhythmia, and ischemic ... ... Grand View Research Logo ...
(Date:2/28/2017)... -- Nordic Nanovector ASA (OSE: NANO) announces its results ... the results by the company,s senior management team will take place ... - details below. ... 2016 was a very successful year for Nordic Nanovector. We achieved ... with our preclinical candidates and build the foundation of R&D innovation ...
(Date:2/27/2017)... -- Halyard Health, Inc. (NYSE: HYH ) today ... 2017 outlook and related key planning assumptions. Executive Summary ... 2 percent increase compared to the prior year. ... million compared to net income of $15 million in the ... $24 million compared to adjusted net income of $27 million ...
Breaking Medicine Technology:
(Date:2/28/2017)... ... February 28, 2017 , ... The role of females ... from military to civilian life. Body image dissatisfaction is largely unexamined among female ... and greater occurrence of chronic mental health conditions than female civilians. Female veterans ...
(Date:2/27/2017)... ... February 27, 2017 , ... Robert E. Burke, MD, PhD, had a ... impoverished upbringing and life experiences could have led him down a much different path. ... Tales of Parenting, Perseverance and Pediatrics,” Dr. Burke shares a personal account of the ...
(Date:2/27/2017)... ... February 27, 2017 , ... Orange County dentist, ... inflammatory gum condition that occurs when the bacteria in plaque infect the gums and ... as a scaling and root planing or SRP, and can include surgical therapies if ...
(Date:2/27/2017)... ... February 27, 2017 , ... ... alcohol treatment programs in British Columbia, Canada, at https://www.sunshinecoasthealthcentre.ca/ , is proud ... The new hire, Mackenzie Alsager, showcases the Centre's commitment to innovation in drug ...
(Date:2/26/2017)... ... 2017 , ... Today, A' Design Awards & Competition has ... Design Awards. , The 7th A' Social Design Award is open for ... with realized projects and conceptual works. , The first phase of the International ...
Breaking Medicine News(10 mins):